BC Extra | Nov 16, 2019
Company News

Novartis gains CHMP support in MS, Cushing syndrome

Included November roundup of EMA’s CHMP were a positive opinion for Mayzent siponimod, which Novartis hopes will become the treatment of choice for active secondary progressive multiple sclerosis. CHMP backed an MAA for Mayzent to...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Week In Review | Nov 2, 2018
Company News

Rigel grants Kissei Asian rights to Tavalisse

Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future indications in Japan, China, Taiwan and Korea. Rigel said it has the option to co-develop the product in the...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
BC Week In Review | Apr 27, 2018
Financial News

Rigel raises $62.4M in follow-on

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) raised $62.4 million on April 19 through the sale of 16 million shares at $3.90 in a follow-on underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and H.C. Wainwright. The price...
Regulatory | Apr 20, 2018
Regulatory

Rigel gets first FDA approval with Tavalisse

FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic thrombocytopenic purpura in adults who have had an insufficient response to a previous treatment. The oral spleen tyrosine kinase...
Financial News | Apr 20, 2018
Financial News

Days after first drug approval, Rigel raises $62.4M

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) raised $62.4 million through the sale of 16 million shares at $3.90 in a follow-on underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and H.C. Wainwright. The price is a tiny...
BC Extra | Apr 17, 2018
Company News

Rigel clinches its first approval with ITP drug

FDA approved an NDA from Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) for Tavalisse fostamatinib to treat chronic idiopathic thrombocytopenic purpura in adults who have had an insufficient response to a previous treatment. The oral spleen tyrosine kinase...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
Items per page:
1 - 10 of 166